Legend Biotech Corp
NASDAQ:LEGN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.28
44.32
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
LEGN
stock under the Base Case scenario is
77.02
USD.
Compared to the current market price of 21.28 USD,
Legend Biotech Corp
is
Undervalued by 72%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Legend Biotech Corp.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Legend Biotech Corp
Balance Sheet Decomposition
Legend Biotech Corp
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 992.7m |
| Receivables | 202.6m |
| Other Current Assets | 46.8m |
| Non-Current Assets | 470.9m |
| PP&E | 253.7m |
| Other Non-Current Assets | 217.2m |
| Current Liabilities | 433.6m |
| Accounts Payable | 249.6m |
| Other Current Liabilities | 183.9m |
| Non-Current Liabilities | 268.1m |
| Long-Term Debt | 260m |
| Other Non-Current Liabilities | 8.1m |
Free Cash Flow Analysis
Legend Biotech Corp
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Legend Biotech Corp
|
Revenue
|
909m
USD
|
|
Cost of Revenue
|
-358.6m
USD
|
|
Gross Profit
|
550.4m
USD
|
|
Operating Expenses
|
-741m
USD
|
|
Operating Income
|
-190.6m
USD
|
|
Other Expenses
|
-49.4m
USD
|
|
Net Income
|
-240m
USD
|
LEGN Profitability Score
Profitability Due Diligence
Legend Biotech Corp's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Legend Biotech Corp's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
LEGN Solvency Score
Solvency Due Diligence
Legend Biotech Corp's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Legend Biotech Corp's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LEGN Price Targets Summary
Legend Biotech Corp
According to Wall Street analysts, the average 1-year price target for
LEGN
is 74.95 USD
with a low forecast of 53.65 USD and a high forecast of 95.55 USD.
Dividends
Current shareholder yield for
LEGN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
LEGN
stock under the Base Case scenario is
77.02
USD.
Compared to the current market price of 21.28 USD,
Legend Biotech Corp
is
Undervalued by 72%.